Pentosan Polysulfate dosing — research reference
FDA label dose and where to find trial regimens
Reviewed by the BestHealingPeptides Editorial Team ·
Pentosan Polysulfate is not a research peptide, and this page does not provide a dosing recommendation. The FDA label for oral Elmiron gives a recommended dose of 300 mg/day taken as one 100 mg capsule three times daily for interstitial cystitis, and the MHRA Drug Safety Update of September 2019 cites the same dose. Doses and regimens used in published human knee osteoarthritis studies are described in the study summaries on the main Pentosan Polysulfate profile. Any decision to take Pentosan Polysulfate belongs with a prescriber.
For full mechanistic context, study summaries, and safety information, see the main Pentosan Polysulfate research profile.
Reported routes of administration
- Oral (Elmiron capsules, interstitial cystitis)
- Subcutaneous injection (knee osteoarthritis trials)
- Intramuscular injection (knee osteoarthritis pilot trial)
Reported half-life
Oral: the FDA label for Elmiron reports that a mean of approximately 6% of a radiolabelled oral dose is absorbed and reaches the systemic circulation, and that plasma radioactivity declined with mean half-lives of 27 and 20 hours after 300 mg and 450 mg oral doses respectively. Subcutaneous and intramuscular pharmacokinetics were not verified for this page.
See the dedicated half-life reference page for fuller pharmacokinetic context.